Publicacións en colaboración con investigadores/as de Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (14)

2024

  1. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates

    Toxicology and Applied Pharmacology, Vol. 487

2022

  1. A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

    EMBO molecular medicine, Vol. 14, Núm. 3, pp. e14552

2021

  1. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity

    Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177

2020

  1. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

    Science Translational Medicine, Vol. 12, Núm. 527

2019

  1. IKKα Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization

    Computational and Structural Biotechnology Journal, Vol. 17, pp. 251-262

2018

  1. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway

    Oral Oncology, Vol. 79, pp. 55-63

2017

  1. A transposon-based analysis reveals RASA1 is involved in triple-negative breast cancer

    Cancer Research, Vol. 77, Núm. 6, pp. 1357-1368

2015

  1. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer

    Oncotarget, Vol. 6, Núm. 39, pp. 42258-42275

  2. Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer

    Clinical Epigenetics, Vol. 7, Núm. 1

  3. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors

    Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576

2014

  1. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer

    Cancer Research, Vol. 74, Núm. 22, pp. 6565-6577

2012

  1. A humanized mouse model of HPV-associated pathology driven by E7 expression

    PLoS ONE, Vol. 7, Núm. 7

  2. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

    PLoS ONE, Vol. 7, Núm. 8

2009

  1. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma

    Cancer Research, Vol. 69, Núm. 3, pp. 1099-1108